Sogayar Ana M C, Machado Flavia R, Rea-Neto Alvaro, Dornas Amselmo, Grion Cintia M C, Lobo Suzana M A, Tura Bernardo R, Silva Carla L O, Cal Ruy G R, Beer Idal, Michels Vilto, Safi Jorge, Kayath Marcia, Silva Eliezer
Hospital Israelita Albert Einstein, São Paulo, Brazil.
Pharmacoeconomics. 2008;26(5):425-34. doi: 10.2165/00019053-200826050-00006.
Sepsis has a high prevalence within intensive care units, with elevated rates of morbidity and mortality, and high costs. Data on sepsis costs are scarce in the literature, and in developing countries such as Brazil these data are largely unavailable.
To assess the standard direct costs of sepsis management in Brazilian intensive care units (ICUs) and to disclose factors that could affect those costs.
This multicentre observational cohort study was conducted in adult septic patients admitted to 21 mixed ICUs of private and public hospitals in Brazil from 1 October 2003 to 30 March 2004. Complete data for all patients admitted to the ICUs were obtained until their discharge or death. We collected only direct healthcare-related costs, defined as all costs related to the ICU stay. Enrolled patients were assessed daily in terms of cost-related expenditures such as hospital fees, operating room fees, gas therapy, physiotherapy, blood components transfusion, medications, renal replacement therapy, laboratory analysis and imaging. Standard unit costs (year 2006 values) were based on the Brazilian Medical Association (AMB) price index for medical procedures and the BRASINDICE price index for medications, solutions and hospital consumables. Medical resource utilization was also assessed daily using the Therapeutic Intervention Scoring System (TISS-28). Indirect costs were not included.
With a mean (standard deviation [SD]) age of 61.1 +/- 19.2 years, 524 septic patients from 21 centres were included in this study. The overall hospital mortality rate was 43.8%, the mean Acute Physiology And Chronic Health Evaluation II (APACHE II) score was 22.3 +/- 5.4, and the mean Sequential Organ Failure Assessment (SOFA) score at ICU admission was 7.5 +/- 3.9. The median total cost of sepsis was $US 9632 (interquartile range [IQR] 4583-18 387; 95% CI 8657, 10 672) per patient, while the median daily ICU cost per patient was $US 934 (IQR 735-1170; 95% CI 897, 963). The median daily ICU cost per patient was significantly higher in non-survivors than in survivors, i.e. $US 1094 (IQR 888-1341; 95% CI 1058, 1157) and $US 826 (IQR 668-982; 95% CI 786, 854), respectively (p < 0.001). For patients admitted to public and private hospitals, we found a median SOFA score at ICU admission of 7.5 and 7.1, respectively (p = 0.02), and the mortality rate was 49.1% and 36.7%, respectively (p = 0.006). Patients admitted to public and private hospitals had a similar length of stay of 10 (IQR 5-19) days versus 9 (IQR 4-16) days (p = 0.091), and the median total direct costs for public ($US 9773; IQR 4643-19 221; 95% CI 8503, 10 818) versus private ($US 9490; IQR 4305-17 034; 95% CI 7610, 11 292) hospitals did not differ significantly (p = 0.37).
The present study provides the first economic analysis of direct costs of sepsis in Brazilian ICUs and reveals that the cost of sepsis treatment is high. Despite similar ICU management, there was a significant difference regarding patient outcome between private and public hospitals. Finally, the median daily costs of non-survivor patients were higher than survivors during ICU stay.
脓毒症在重症监护病房中普遍存在,发病率和死亡率高,成本高昂。脓毒症成本的数据在文献中很少见,在巴西等发展中国家,这些数据基本无法获取。
评估巴西重症监护病房(ICU)中脓毒症管理的标准直接成本,并揭示可能影响这些成本的因素。
这项多中心观察性队列研究于2003年10月1日至2004年3月30日在巴西21家私立和公立医院的混合ICU中收治的成年脓毒症患者中进行。获取ICU收治的所有患者直至出院或死亡的完整数据。我们仅收集与医疗保健直接相关的成本,定义为与ICU住院相关的所有成本。对入组患者每天进行评估,记录与成本相关的支出,如住院费、手术室费、气体治疗、物理治疗、血液成分输血、药物、肾脏替代治疗、实验室分析和影像学检查。标准单位成本(2006年值)基于巴西医学协会(AMB)的医疗程序价格指数以及BRASINDICE的药物、溶液和医院耗材价格指数。每天还使用治疗干预评分系统(TISS - 28)评估医疗资源利用情况。不包括间接成本。
本研究纳入了来自21个中心的524例脓毒症患者,平均(标准差[SD])年龄为61.1±19.2岁。总体医院死亡率为43.8%,急性生理与慢性健康状况评估II(APACHE II)平均评分为22.3±5.4,ICU入院时序贯器官衰竭评估(SOFA)平均评分为7.5±3.9。脓毒症患者的总费用中位数为每位患者9632美元(四分位间距[IQR] 4583 - 18387;95%置信区间8657, 10672),而每位患者每天的ICU费用中位数为934美元(IQR 735 - 1170;95%置信区间897, 963)。非幸存者每位患者每天的ICU费用中位数显著高于幸存者,分别为1094美元(IQR 888 - 1341;95%置信区间1058, 1157)和826美元(IQR 668 - 982;95%置信区间786, 854)(p < 0.001)。对于入住公立和私立医院的患者,我们发现ICU入院时SOFA评分中位数分别为7.5和7.1(p = 0.02),死亡率分别为49.1%和36.7%(p = 0.006)。入住公立和私立医院的患者住院时间相似,分别为10(IQR 5 - 19)天和9(IQR 4 - 16)天(p = 0.091),公立(9773美元;IQR 4643 - 19221;95%置信区间8503, 10818)和私立(9490美元;IQR 4305 - 17034;95%置信区间7610, 11292)医院的总直接成本中位数无显著差异(p = 0.37)。
本研究首次对巴西ICU中脓毒症的直接成本进行了经济分析,揭示了脓毒症治疗成本高昂。尽管ICU管理相似,但公立和私立医院患者的结局存在显著差异。最后,非幸存者患者在ICU住院期间的每日成本中位数高于幸存者。